Drug Trial Radar · NCT05069610
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
Last checked: Nov 19, 2026Latest source record: Dec 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 21, 2022
Primary completion
Oct 31, 2023
Study completion Dec 18, 2023
Sponsor
- Lead sponsor
- Advagene Biopharma Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
AD17002 has demonstrated superior safety and efficacy as a nasal adjuvant function to an influenza vaccine in two completed clinical studies, and has innate immune modulatory and anti-inflammatory properties which could potentially be an effective treatment for SARS-CoV-2 infection. This Phase 2a, multi-center study is set up to assess the safety, tolerability, and potential efficacy of AD17002 in participants with mild to moderate COVID-19. The Immunogenicity of repeated doses of AD17002 will also be explored.
Conditions
- COVID-19
Interventions
AD17002Biological
A recombinant protein
Placebo (Formulation buffer)Biological
Formulation buffer
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of participants who experience adverse eventsTime frame: 7 weeks
- The proportion of participants with treatment-emergent adverse events (TEAE) leading to investigational medicinal products (IMPs) discontinuationTime frame: 7 weeks
- The nasal tolerability to investigational medicinal products (IMPs)Time frame: 7 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Advagene Biopharma
Taipei, Taiwan
Chang Gun Medical Foundation
Taoyuan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.